TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07431112: Phase 1, Open-Label, Single Ascending Dose and Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered AIR-001 in Adults With AATD Due to PiZZ Genotype

Sponsor: AIRNA Corporation · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 54 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$3,702,464

Rescue Site Savings

+$2,438,208

Unlock Full NCT07431112 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07431112 Rescue Dossier →